The study, published in Transplant International, enrolled 80 heart transplant recipients and analyzed 299 plasma samples using a domestically developed next-generation sequencing assay. The technology rests on a simple biological premise: when donor heart cells die, they release their DNA into the recipient’s bloodstream. Because donor and recipient genomes differ, this donor-derived cell-free DNA, or dd-cfDNA, can be quantified as a fraction of total circulating DNA. Rising levels signal graft injury, potentially long before symptoms or echocardiographic changes appear.

What makes the Chinese assay distinctive is its genetic architecture. Most commercial dd-cfDNA tests, including the widely used AlloSure platform, distinguish donor from recipient DNA by genotyping single nucleotide polymorphisms, single-letter genome variations. The new assay instead targets 48 insertion-deletion markers, or Indels, stretches of DNA that are either present or absent entirely. These markers were selected for minor allele frequencies of 0.4 to 0.6 in East Asian populations, a range that maximizes the probability that any given donor-recipient pair will differ at enough sites for reliable quantification. The researchers argue that Indel-based detection may overcome the single-base resolution limits of short-read sequencing and reduce background noise, while the multiplexing capacity of sequencing surpasses digital PCR by assessing dozens of loci simultaneously, protecting against single-marker failure.

To interpret any dd-cfDNA measurement, clinicians first need to know what normal looks like. The team established this with a reference cohort of 42 clinically stable recipients, monitored at one, two, four, eight, 24, and 48 weeks after transplantation. Levels peaked in the first week, a median of 0.29%, reflecting the expected wave of ischemia-reperfusion injury from the surgery itself, then declined steadily. A stable trend emerged around week four, and by week eight levels had reached their nadir of 0.19%, remaining low through one year. Statistical modeling using generalized estimating equations confirmed significant declines from weeks one and two to week eight, with no meaningful change thereafter. The practical implication is that dd-cfDNA signals obtained before eight weeks post-transplant should be interpreted cautiously, since early levels are confounded by surgical injury.

The diagnostic core of the study involved 41 patients undergoing biopsy for clinical suspicion of rejection, yielding 42 biopsies paired with 56 dd-cfDNA samples. Pathologists graded the specimens according to International Society for Heart and Lung Transplantation criteria while remaining blinded to the blood results. The findings were striking: patients with biopsy-proven acute rejection had a median dd-cfDNA of 0.87%, nearly four times the 0.23% seen in those without rejection, a difference with a P value below 0.001. Levels rose in parallel with histological severity. Biopsies showing significant acute cellular rejection, grade 2R or higher, averaged 0.81%, while mild grade 1R rejection did not differ from rejection-free tissue. Antibody-mediated rejection showed an even steeper gradient, with grade 2 or higher AMR reaching 1.04%, consistent with the biology of humoral rejection, in which antibodies attack graft endothelium, a rich source of released DNA.

Receiver operating characteristic analysis identified 0.33% as the optimal composite threshold for detecting acute rejection, yielding an area under the curve of 0.874, sensitivity of 81.0%, and specificity of 85.7%. For antibody-mediated rejection alone, a higher cutoff of 0.69% performed best, with 80.0% sensitivity and 92.9% specificity. Notably, the 0.33% threshold is numerically higher than the 0.20% to 0.25% cutoffs established in predominantly Western cohorts using SNP-based assays. The researchers attribute this discrepancy to a combination of possible ethnic variations in cell-free DNA metabolism and immunological responses, fundamental methodological differences between Indel-based and SNP-based platforms, and cohort selection biases. Without head-to-head comparison on identical samples, the relative contributions of biology versus technology cannot be disentangled, a limitation the authors acknowledge openly.

The study also demonstrated that dd-cfDNA tracks treatment response. In 14 patients with paired measurements before and two weeks after anti-rejection therapy, median levels fell from 0.98% to 0.38%, a statistically significant decline that paralleled substantial drops in NT-proBNP, a marker of cardiac strain. When stratified by rejection type, the reduction was significant only in the cellular rejection subgroup; antibody-mediated rejection showed a more modest, non-significant decline, suggesting that resolution of humoral graft injury may require a longer observation window than two weeks. Left ventricular ejection fraction, meanwhile, did not change significantly over the same period, hinting that structural recovery lags behind the molecular resolution of injury.

Perhaps the most biologically revealing finding concerns graft function. Across the entire cohort, dd-cfDNA showed a graded inverse correlation with left ventricular ejection fraction: patients with severely reduced function below 50% had the highest levels, those with preserved function above 60% the lowest. Yet when the analysis was stratified by rejection status, the inverse association persisted only in the rejection subgroup and vanished among rejection-free patients. This suggests that dd-cfDNA specifically reflects immune-mediated myocardial injury rather than serving as a general marker of cardiac dysfunction. Discordant cases reinforced the point: among 12 patients with elevated dd-cfDNA despite preserved ejection fraction, 11 had biopsy-proven rejection, indicating that molecular injury can precede functional deterioration, while patients with reduced function but low dd-cfDNA typically had no rejection on biopsy, their dysfunction attributable to non-immunological factors such as altered loading conditions or arrhythmias.

The researchers are careful about what their threshold can and cannot do. Because their for-cause biopsy cohort had a high rejection prevalence of roughly 60%, the positive predictive value of 89.5% is inflated relative to routine surveillance settings, while the negative predictive value of 75.0% falls well short of the 94% or higher figures reported in low-prevalence surveillance studies. In practical terms, a dd-cfDNA level at or above 0.33% should trigger comprehensive evaluation, but a low value should never be used in isolation to defer biopsy. The authors frame the test as better suited to a rule-in than a rule-out strategy, an adjunctive tool within multimodal monitoring rather than a replacement for histology. They also note that infection, which was significantly more frequent in the rejection group, may independently elevate dd-cfDNA and could not be adjusted for given the sample size.

The study’s limitations are substantial and the authors state them plainly: a single center, modest sample size, only nine antibody-mediated rejection events, no protocol biopsies in the reference cohort, and no direct benchmarking against commercial assays. Internal validation through 1,000 hierarchical bootstrap resamples produced point estimates clustered near 76% but with confidence intervals spanning roughly 37 to 40 percentage points, underscoring the preliminary nature of the findings. Still, as the first prospective evaluation of dd-cfDNA in a Chinese heart transplant population using a domestically developed platform, the study fills a genuine gap. External validation in multicenter cohorts is required before routine clinical implementation, but the trajectory is clear: the era of monitoring a transplanted heart through a simple blood draw, calibrated to the genetics of the population it serves, is drawing measurably closer.

Subject of Research: Heart Transplantation

Article Title: Prospective evaluation of donor-derived cell-free DNA for noninvasive detection of acute rejection in an Asian heart transplant population

Article References: Prospective evaluation of donor-derived cell-free DNA for noninvasive detection of acute rejection in an Asian heart transplant population. (n.d.). https://doi.org/10.3389/ti.2026.16415

Image Credits: AI Generated

DOI: 10.3389/ti.2026.16415

Keywords: heart transplantation, donor-derived cell-free DNA, acute rejection, liquid biopsy, next-generation sequencing, transplant immunology, Prospective, evaluation, donor-derived, cell-free, noninvasive, detection

The research team, led by Su-Hyeon Lee and Deok-Gie Kim, with corresponding authors Byungjin Hwang and Dong Jin Joo, took an unusually rigorous approach to a difficult clinical problem. They recruited 20 liver transplant recipients and collected paired samples of peripheral blood mononuclear cells, the circulating immune cells that include lymphocytes and monocytes, both before surgery and after transplantation. Ten of these patients went on to develop acute rejection and ten did not. Crucially, the two groups were matched for a battery of clinical variables that could otherwise confound the analysis, including age, sex, hepatocellular carcinoma status, autoimmune disease status, ABO blood group compatibility, and donor age. By controlling for these factors, the investigators could be more confident that the immunological differences they found were genuinely linked to rejection rather than to incidental patient characteristics.

Technically, the study is a tour de force of single-cell multi-omics. Rather than averaging gene expression across bulk tissue, the team used single-cell RNA sequencing to profile 88,940 high-quality individual cells, preserving the identity and state of each immune cell. They paired this transcriptomic readout with T cell receptor sequencing, which reads the unique genetic rearrangements that give each T cell its antigen-specific receptor. This combination allowed them to track not only which cell types were present and what genes they were expressing, but also how T cell clones expanded, contracted, and diversified over time. On top of the sequencing data, the researchers layered computational analyses of gene regulatory networks and intercellular communication, reconstructing the signaling conversations between immune cell populations that precede and accompany rejection.

The most striking finding is that the immune systems of future rejecters looked different before transplantation. Patients who later developed acute rejection already showed a distinct pre-transplant immune state compared with those who tolerated their new livers. Natural killer cells in the rejection group displayed an inflammatory activation profile with enhanced responsiveness to interferon, a family of signaling proteins central to antiviral and immune defense responses. Monocytes, the innate immune cells that patrol the blood and seed tissues, showed altered composition and transcriptional programs dominated by interferon-associated signatures. Together, these observations suggest a systemic, low-grade inflammatory readiness in the circulation of patients whose immune systems would later turn against the graft.

The adaptive immune side of the story was equally revealing. Before surgery, recipients who went on to reject showed a skewing of their CD8 T cell compartment toward effector memory states. Effector memory CD8 T cells are the rapid-response soldiers of the immune system: they circulate in the blood and peripheral tissues, and when they encounter their target antigen they can immediately deploy cytotoxic machinery without the delay required for naive T cells to differentiate. A pre-existing bias toward this compartment means the patient carries a standing army of cytotoxic cells primed for fast action, a configuration that could plausibly accelerate an attack on donor tissue once transplantation delivers a flood of foreign antigens.

After transplantation, the divergence between the two groups did not close; it widened in specific ways. Despite receiving standard immunosuppression, rejection patients maintained heightened overall immune activity. The team observed an expansion of KIR-expressing effector memory CD8 T cell populations in these patients. KIR, or killer cell immunoglobulin-like receptors, are molecules classically associated with natural killer cells that tune their reactivity to self, but their expression on CD8 T cells marks a subset with distinctive effector properties. The rejection group also showed increased expression of IRF1, a transcription factor that sits downstream of interferon signaling and orchestrates inflammatory gene programs in CD8 T cells. In other words, the post-transplant immune landscape of rejecters retained an activated, interferon-driven character that immunosuppression failed to fully extinguish.

To move from descriptive biology toward clinical utility, the researchers searched for genes whose expression reliably distinguished rejecting from non-rejecting patients across multiple time points. They identified 15 robust acute rejection-associated genes that were consistently detected before and after transplantation, and then validated a subset of these genes in liver biopsy tissue from the patients. This cross-validation is important: it links the circulating blood signature to the actual immunological battleground inside the graft, supporting the idea that a peripheral blood test could serve as a proxy for processes occurring in the transplanted liver. A blood-based biomarker panel built on such genes could, in principle, flag high-risk patients before rejection becomes clinically manifest, allowing clinicians to intensify monitoring or tailor immunosuppressive regimens without resorting to repeated biopsies.

The implications reach beyond liver transplantation. Acute cellular rejection is fundamentally a problem of immune recognition and memory, and the Yonsei study demonstrates that the relevant information is encoded in the composition and activation state of circulating immune cells. The finding that pre-transplant immune states predispose recipients to rejection challenges the traditional view of rejection as a purely post-transplant event driven by donor-recipient mismatch alone. Instead, the recipient’s baseline immune configuration, shaped by their disease history, viral exposures, and inflammatory milieu, appears to set the stage for how the immune system will respond to the graft. This reframing aligns with a broader trend in transplant immunology toward precision medicine, in which immunological risk stratification replaces one-size-fits-all immunosuppression.

There are, of course, important caveats. The study involved 20 carefully matched patients, a sample size appropriate for discovery but too small to support immediate clinical deployment of a diagnostic test. The 15-gene signature and the cellular features identified will need validation in larger, independent, and ideally multi-center cohorts before they can inform treatment decisions. It also remains to be seen whether the signatures generalize across different donor types, immunosuppressive protocols, and causes of liver failure. Nonetheless, the methodological framework, integrating single-cell transcriptomics, T cell receptor repertoire tracking, regulatory network inference, and tissue validation, provides a template that other transplant programs can adopt to build the evidence base needed for clinical translation.

For patients awaiting a liver, the promise is tangible: a pre-operative blood draw that reveals whether their immune system is primed for conflict, and post-operative monitoring that catches rejection in its earliest molecular stages rather than after tissue damage has occurred. For the field of transplant immunology, the study adds a detailed cellular and molecular atlas of how rejection unfolds in the human circulation, from interferon-primed natural killer cells and interferon-signature monocytes to KIR-expressing effector memory CD8 T cells and IRF1-driven inflammatory programs. As single-cell sequencing becomes faster and cheaper, the vision of routine immune profiling before and after organ transplantation moves closer to reality, and with it the possibility of preventing rejection rather than merely treating it.

Subject of Research: Single-cell RNA sequencing and T cell receptor repertoire analysis of immune signatures associated with acute liver allograft rejection

Article Title: Integrative single-cell RNA-seq and TCR repertoire analysis reveals distinct immunological features of acute liver allograft rejection

Article References: Lee, S.-H., Kim, D.-G., Cho, Y., Min, E.-K., Lee, J. G., Kim, M. S., Park, S., Hwang, B., & Joo, D. J. (2026). Integrative single-cell RNA-seq and TCR repertoire analysis reveals distinct immunological features of acute liver allograft rejection. Genome Medicine. https://doi.org/10.1186/s13073-026-01753-4

Image Credits: AI Generated

DOI: 10.1186/s13073-026-01753-4

Keywords: liver transplantation, acute rejection, single-cell RNA sequencing, T cell receptor repertoire, CD8 T cells, natural killer cells, monocytes, interferon signaling, IRF1, biomarkers, immunosuppression, Genome Medicine